Gonadotropin-releasing hormone and ovarian cancer: A functional and mechanistic overview

FEBS Journal

Volumn 275, Issue 22, 2008, Pages 5496-5511

  So, Wai Kin ^a   Cheng, Jung Chien ^a   Poon, Song Ling ^a   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apoptosis; G protein; GnRH; Gonadotropin releasing hormone; Growth factor; Invasion; MAPK; Migration; Ovarian cancer; Proliferation

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; BUSERELIN; CETRORELIX; DOXORUBICIN; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GOSERELIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; LEUPRORELIN; MITOGEN ACTIVATED PROTEIN KINASE; PERTUSSIS TOXIN; PLATINUM DERIVATIVE; PROTEIN KINASE C; TRIPTORELIN;

APOPTOSIS; AUTOCRINE EFFECT; CANCER CELL; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; GONADOTROPIN SECRETING CELL; HORMONE ACTION; HORMONE RELEASE; HUMAN; HYPOPHYSIS; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN NEOPLASMS;

EID: 54849405953     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06679.x     Document Type: Short Survey

References (127)

1. Fathalla MF (1971) Incessant ovulation - a factor in ovarian neoplasia? Lancet 2, 163.
2. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK Henderson BE (1979) 'Incessant ovulation' and ovarian cancer. Lancet 2, 170 173.
3. Cramer DW Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71, 717 721.
4. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH Studd JW (1976) Hormonal profiles after the menopause. Br Med J 2, 784 787.
5. Scaglia H, Medina M, Pinto-Ferreira AL, Vazques G, Gual C Perez-Palacios G (1976) Pituitary LH and FSH secretion and responsiveness in women of old age. Acta Endocrinol (Copenh) 81, 673 679.
6. Sell A, Bertelsen K, Andersen JE, Stroyer I Panduro J (1990) Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 37, 367 373.
7. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A Hughes C (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88, 554 559.
8. Whittemore AS, Harris R Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 136, 1212 1220.
9. La Vecchia C Franceschi S (1999) Oral contraceptives and ovarian cancer. Eur J Cancer Prev 8, 297 304.
10. Shoham Z (1994) Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil Steril 62, 433 448.
11. Rao BR Slotman BJ (1991) Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12, 14 26.
12. Parrott JA, Doraiswamy V, Kim G, Mosher R Skinner MK (2001) Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172, 213 222.
13. Syed V, Ulinski G, Mok SC, Yiu GK Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61, 6768 6776.
14. Choi KC, Kang SK, Tai CJ, Auersperg N Leung PC (2002) Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 87, 2245 2253.
15. Choi JH, Choi KC, Auersperg N Leung PC (2005) Gonadotropins upregulate the epidermal growth factor receptor through activation of mitogen-activated protein kinases and phosphatidyl-inositol-3-kinase in human ovarian surface epithelial cells. Endocr Relat Cancer 12, 407 421.
16. Choi JH, Choi KC, Auersperg N Leung PC (2004) Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89, 5508 5516.
17. Choi JH, Choi KC, Auersperg N Leung PC (2006) Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 66, 3912 3920.
18. Limonta P, Moretti RM, Marelli MM Motta M (2003) The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol 24, 279 295.
19. Peterson CM, Jolles CJ, Carrell DT, Straight RC, Jones KP, Poulson AM Jr. Hatasaka HH (1994) GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience. Gynecol Oncol 52, 26 30.
20. Kang SK, Cheng KW, Ngan ES, Chow BK, Choi KC Leung PC (2000) Differential expression of human gonadotropin-releasing hormone receptor gene in pituitary and ovarian cells. Mol Cell Endocrinol 162, 157 166.
21. Irmer G, Burger C, Muller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD Emons G (1995) Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55, 817 822.
22. Srkalovic G, Schally AV, Wittliff JL, Day TG Jr. Jenison EL (1998) Presence and characteristics of receptors for [D-Trp6]luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 12, 489 498.
23. Imai A, Ohno T, Ohsuye K Tamaya T (1994) Expression of gonadotropin-releasing hormone receptor in human epithelial ovarian carcinoma. Ann Clin Biochem 31, 550 555.
24. Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F Knuppen R (1989) Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25, 215 221.
25. Imai A, Ohno T, Iida K, Fuseya T, Furui T Tamaya T (1994) Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer 74, 2555 2561.
26. Yin H, Cheng KW, Hwa HL, Peng C, Auersperg N Leung PC (1998) Expression of the messenger RNA for gonadotropin-releasing hormone and its receptor in human cancer cell lines. Life Sci 62, 2015 2023.
27. Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B Emons G (2004) Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151, 141 149.
28. Choi KC, Auersperg N Leung PC (2001) Expression and antiproliferative effect of a second form of gonadotropin-releasing hormone in normal and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 86, 5075 5078.
29. Yano T, Pinski J, Radulovic S Schally AV (1994) Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 91, 1701 1705.
30. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD Schally AV (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53, 5439 5446.
31. Yano T, Pinski J, Halmos G, Szepeshazi K, Groot K Schally AV (1994) Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA 91, 7090 7094.
32. Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N Leung PC (2000) Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 141, 72 80.
33. Irmer G, Burger C, Ortmann O, Schulz KD Emons G (1994) Expression of luteinizing hormone releasing hormone and its mRNA in human endometrial cancer cell lines. J Clin Endocrinol Metab 79, 916 919.
34. Arencibia JM Schally AV (2000) Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line. Int J Oncol 16, 1009 1013.
35. Emons G, Weiss S, Ortmann O, Grundker C Schulz KD (2000) LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol 142, 665 670.
36. Kang SK, Cheng KW, Nathwani PS, Choi KC Leung PC (2000) Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. Endocrine 13, 297 304.
37. Grundker C, Gunthert AR, Millar RP Emons G (2002) Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87, 1427 1430.
38. Emons G, Schroder B, Ortmann O, Westphalen S, Schulz KD Schally AV (1993) High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab 77, 1458 1464.
39. Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H Huidobro C (2006) Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest 24, 261 268.
40. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM Schally AV (1992) Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat 21, 35 45.
41. Kim KY, Choi KC, Auersperg N Leung PC (2006) Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 13, 211 220.
42. Kim KY, Choi KC, Park SH, Auersperg N Leung PC (2005) Extracellular signal-regulated protein kinase, but not c-Jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. J Clin Endocrinol Metab 90, 1670 1677.
43. Gunthert AR, Grundker C, Hollmann K Emons G (2002) Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochem Biophys Res Commun 294, 11 15.
44. Kim JH, Park DC, Kim JW, Choi YK, Lew YO, Kim DH, Jung JK, Lim YA Namkoong SE (1999) Antitumor effect of GnRH agonist in epithelial ovarian cancer. Gynecol Oncol 74, 170 180.
45. Thompson MA, Adelson MD Kaufman LM (1991) Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum-free medium. J Clin Endocrinol Metab 72, 1036 1041.
46. Tang X, Yano T, Osuga Y, Matsumi H, Yano N, Xu J, Wada O, Koga K, Kugu K, Tsutsumi O et al. (2002) Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J Clin Endocrinol Metab 87, 3721 3727.
47. Ohta H, Sakamoto H Satoh K (1998) In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Lett 134, 111 118.
48. Kraus S, Levy G, Hanoch T, Naor Z Seger R (2004) Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Res 64, 5736 5744.
49. Motomura S (1998) Induction of apoptosis in ovarian carcinoma cell line by gonadotropin-releasing hormone agonist. Kurume Med J 45, 27 32.
50. Imai A, Sugiyama M, Furui T Tamaya T (2006) Gi protein-mediated translocation of serine/threonine phosphatase to the plasma membrane and apoptosis of ovarian cancer cell in response to gonadotropin-releasing hormone antagonist cetrorelix. J Obstet Gynaecol 26, 37 41.
51. Imai A, Horibe S, Takagi A, Ohno T Tamaya T (1997) Frequent expression of Fas in gonadotropin-releasing hormone receptor-bearing tumors. Eur J Obstet Gynecol Reprod Biol 74, 73 78.
52. Imai A, Takagi A, Horibe S, Takagi H Tamaya T (1998) Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab 83, 427 431.
53. Grundker C, Schulz K, Gunthert AR Emons G (2000) Luteinizing hormone-releasing hormone induces nuclear factor kappaB-activation and inhibits apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 85, 3815 3820.
54. Sugiyama M, Imai A, Furui T Tamaya T (2005) Gonadotropin-releasing hormone retards doxorubicin-induced apoptosis and serine/threonine phosphatase inhibition in ovarian cancer cells. Oncol Rep 13, 813 817.
55. Fister S, Schlotawa L, Gunthert AR, Emons G Grundker C (2007) Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells. Gynecol Endocrinol 24, 1 6.
56. Imai A, Sugiyama M, Furui T, Tamaya T Ohno T (2007) Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 63, 102 106.
57. Kim KY, Choi KC, Park SH, Chou CS, Auersperg N Leung PC (2004) Type II gonadotropin-releasing hormone stimulates p38 mitogen-activated protein kinase and apoptosis in ovarian cancer cells. J Clin Endocrinol Metab 89, 3020 3026.
58. Fister S, Gunthert AR, Emons G Grundker C (2007) Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo. Cancer Res 67, 1750 1756.
59. Chien CH, Chen CH, Lee CY, Chang TC, Chen RJ Chow SN (2004) Detection of gonadotropin-releasing hormone receptor and its mRNA in primary human epithelial ovarian cancers. Int J Gynecol Cancer 14, 451 458.
60. Chou CS, MacCalman CD Leung PC (2003) Differential effects of gonadotropin-releasing hormone I and II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human decidual stromal cells in vitro. J Clin Endocrinol Metab 88, 3806 3815.
61. Chou CS, Zhu H, MacCalman CD Leung PC (2003) Regulatory effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the levels of matrix metalloproteinase (MMP)-2, MMP-9, and tissue inhibitor of metalloproteinases-1 in primary cultures of human extravillous cytotrophoblasts. J Clin Endocrinol Metab 88, 4781 4790.
62. Chou CS, Zhu H, Shalev E, MacCalman CD Leung PC (2002) The effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human extravillous cytotrophoblasts in vitro. J Clin Endocrinol Metab 87, 5594 5603.
63. Cheung LW, Leung PC Wong AS (2006) Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 66, 10902 10910.
64. Chen CL, Cheung LW, Lau MT, Choi JH, Auersperg N, Wang HS, Wong AS Leung PC (2007) Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. Endocrine 31, 311 320.
65. Dondi D, Festuccia C, Piccolella M, Bologna M Motta M (2006) GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 15, 393 400.
66. Huang YT, Hwang JJ, Lee LT, Liebow C, Lee PP, Ke FC, Lo TB, Schally AV Lee MT (2002) Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells. Int J Cancer 99, 505 513.
67. von Alten J, Fister S, Schulz H, Viereck V, Frosch KH, Emons G Grundker C (2006) GnRH analogs reduce invasiveness of human breast cancer cells. Breast Cancer Res Treat 100, 13 21.
68. Dobkin-Bekman M, Naidich M, Pawson AJ, Millar RP, Seger R Naor Z (2006) Activation of mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol Cell Endocrinol 252, 184 190.
69. Kraus S, Naor Z Seger R (2001) Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor. Arch Med Res 32, 499 509.
70. Krsmanovic LZ, Mores N, Navarro CE, Arora KK Catt KJ (2003) An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion. Proc Natl Acad Sci USA 100, 2969 2974.
71. Grosse R, Schmid A, Schoneberg T, Herrlich A, Muhn P, Schultz G Gudermann T (2000) Gonadotropin-releasing hormone receptor initiates multiple signaling pathways by exclusively coupling to G(q/11) proteins. J Biol Chem 275, 9193 9200.
72. Grundker C, Volker P Emons G (2001) Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase. Endocrinology 142, 2369 2380.
73. Imai A, Takagi H, Horibe S, Fuseya T Tamaya T (1996) Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J Clin Endocrinol Metab 81, 3249 3253.
74. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M Motta M (1999) The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140, 5250 5256.
75. Millar RP Pawson AJ (2004) Outside-in and inside-out signaling: the new concept that selectivity of ligand binding at the gonadotropin-releasing hormone receptor is modulated by the intracellular environment. Endocrinology 145, 3590 3593.
76. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276, 24433 24436.
77. Millar RP, Pawson AJ, Morgan K, Rissman EF Lu ZL (2008) Diversity of actions of GnRHs mediated by ligand-induced selective signaling. Front Neuroendocrinol 29, 17 35.
78. Grundker C, Volker P, Schulz KD Emons G (2000) Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecol Oncol 78, 194 202.
79. Eicke N, Gunthert AR, Emons G Grundker C (2006) GnRH-II agonist [D-Lys6]GnRH-II inhibits the EGF-induced mitogenic signal transduction in human endometrial and ovarian cancer cells. Int J Oncol 29, 1223 1229.
80. Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R et al. (2001) A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci USA 98, 9636 9641.
81. Kimura A, Ohmichi M, Kurachi H, Ikegami H, Hayakawa J, Tasaka K, Kanda Y, Nishio Y, Jikihara H, Matsuura N et al. (1999) Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line. Cancer Res 59, 5133 5142.
82. Yates C, Wells A Turner T (2005) Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline. Br J Cancer 92, 366 375.
83. Wells A, Souto JC, Solava J, Kassis J, Bailey KJ Turner T (2002) Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clin Cancer Res 8, 1251 1257.
84. Yamamoto H, Sato H, Shibata S, Murata M, Fukuda J Tanaka T (2001) Involvement of annexin V in the antiproliferative effect of GnRH agonist on cultured human uterine leiomyoma cells. Mol Hum Reprod 7, 169 173.
85. Kang SK, Tai CJ, Nathwani PS, Choi KC Leung PC (2001) Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone in human granulosa-luteal cells. Endocrinology 142, 671 679.
86. Weck J, Fallest PC, Pitt LK Shupnik MA (1998) Differential gonadotropin-releasing hormone stimulation of rat luteinizing hormone subunit gene transcription by calcium influx and mitogen-activated protein kinase-signaling pathways. Mol Endocrinol 12, 451 457.
87. Yokoi T, Ohmichi M, Tasaka K, Kimura A, Kanda Y, Hayakawa J, Tahara M, Hisamoto K, Kurachi H Murata Y (2000) Activation of the luteinizing hormone beta promoter by gonadotropin-releasing hormone requires c-Jun NH2-terminal protein kinase. J Biol Chem 275, 21639 21647.
88. Bonfil D, Chuderland D, Kraus S, Shahbazian D, Friedberg I, Seger R Naor Z (2004) Extracellular signal-regulated kinase, Jun N-terminal kinase, p38, and c-Src are involved in gonadotropin-releasing hormone-stimulated activity of the glycoprotein hormone follicle-stimulating hormone beta-subunit promoter. Endocrinology 145, 2228 2244.
89. Kang SK, Tai CJ, Cheng KW Leung PC (2000) Gonadotropin-releasing hormone activates mitogen-activated protein kinase in human ovarian and placental cells. Mol Cell Endocrinol 170, 143 151.
90. Marshall CJ (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179 185.
91. Grundker C, Schlotawa L, Viereck V Emons G (2001) Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin. Eur J Endocrinol 145, 651 658.
92. Emons G, Muller V, Ortmann O, Grossmann G, Trautner U, von Struckrad B, Schulz KD Schally AV (1996) Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. Int J Oncol 19, 1129 1137.
93. Leppa S Bohmann D (1999) Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene 18, 6158 6162.
94. Grundker C Emons G (2003) Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol 1, 65 71.
95. Auersperg N, Wong AS, Choi KC, Kang SK Leung PC (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22, 255 288.
96. Lee MT, Liebow C, Kamer AR Schally AV (1991) Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA 88, 1656 1660.
97. Imai A, Furui T, Tamaya T Mills GB (2000) A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. J Clin Endocrinol Metab 85, 3370 3375.
98. Imai A, Horibe S, Takagi A Tamaya T (1997) Gi protein activation of gonadotropin-releasing hormone-mediated protein dephosphorylation in human endometrial carcinoma. Am J Obstet Gynecol 176, 371 376.
99. Imai A, Takagi H, Furui T, Horibe S, Fuseya T Tamaya T (1996) Evidence for coupling of phosphotyrosine phosphatase to gonadotropin-releasing hormone receptor in ovarian carcinoma membrane. Cancer 77, 132 137.
100. Sugiyama M, Imai A, Furui T Tamaya T (2003) Independent action of serine/threonine protein phosphatase in ovarian cancer plasma membrane and cytosol during gonadotropin-releasing hormone stimulation. Oncol Rep 10, 1885 1889.
101. Shirahige Y, Cook C, Pinski J, Halmos G, Nair R Schally AV (1994) Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol 5, 1031 1035.
102. Chatzistamou I, Schally AV, Szepeshazi K, Groot K, Hebert F Arencibia JM (2001) Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Cancer Lett 171, 37 45.
103. Moretti RM, Marelli MM, Dondi D, Poletti A, Martini L, Motta M Limonta P (1996) Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. J Clin Endocrinol Metab 81, 3930 3937.
104. Marelli MM, Moretti RM, Dondi D, Motta M Limonta P (1999) Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 140, 329 334.
105. Lamharzi N, Halmos G, Jungwirth A Schally AV (1998) Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 13, 429 435.
106. Duffaud F, van der Burg ME, Namer M, Vergote I, Willemse PHB, ten Bokkel Huinink W, Guastalla JP, Nooij MA, Kerbrat P, Piccart M et al. (2001) D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study. Anticancer Drugs 12, 159 162.
107. Kavanagh JJ, Roberts W, Townsend P Hewitt S (1989) Leuprolide acetate in the treatment of refractory or persistent epithelial ovarian cancer. J Clin Oncol 7, 115 118.
108. Bruckner HW Motwani BT (1989) Treatment of advanced refractory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol 161, 1216 1218.
109. Miller DS, Brady MF Barrett RJ (1992) A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 15, 125 128.
110. Marinaccio M, D'Addario V, Serrati A, Pinto V Cagnazzo G (1996) Leuprolide acetate as a salvage-therapy in relapsed epithelial ovarian cancer. Eur J Gynaecol Oncol 17, 286 288.
111. Paskeviciute L, Roed H Engelholm S (2002) No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Gynecol Oncol 86, 297 301.
112. du BA, Meier W, Luck HJ, Emon G, Moebus V, Schroeder W, Costa S, Bauknecht T, Olbricht S, Jackisch C et al. (2002) Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13, 251 257.
113. Balbi G, Piano LD, Cardone A Cirelli G (2004) Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer 14, 799 803.
114. Parmar H, Phillips RH, Rustin G, Lightman SL Schally AV (1988) Therapy of advanced ovarian cancer with D-Trp-6-LH-RH (decapeptyl) microcapsules. Biomed Pharmacother 42, 531 538.
115. Jager W, Wildt L Lang N (1989) Some observations on the effect of a GnRH analog in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 32, 137 148.
116. Carnino F, Iskra L, Fuda G, Foglia G, Odicino F, Bruzzone M, Chiara S, Gadducci A Ragni N (1994) The treatment of progressive ovarian carcinoma with D-Trp-LHRH (Decapeptyl). Gruppo Oncologico Nord ovest (GONO). Eur J Cancer 30A, 1903 1904.
117. Jager W, Sauerbrei W, Beck E, Maassen V, Stumpfe M, Meier W, Kuhn W Janicke F (1995) A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res 15, 2639 2642.
118. Ron IG, Wigler N, Merimsky O, Inbar MJ Chaitchik S (1995) A phase II trial of D-Trp-6-LHRH (decapeptyl) in pretreated patients with advanced epithelial ovarian cancer. Cancer Invest 13, 272 275.
119. Sevelda P, Vavra N, Fitz R, Barrada M, Salzer H, Baur M Dittrich C (1992) Goserelin: a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer. Int J Gynecol Cancer 2, 160 162.
120. Lind MJ, Cantwell BM, Millward MJ, Robinson A, Proctor M, Simmons D, Carmichael J Harris AL (1992) A phase II trial of goserelin (Zoladex) in relapsed epithelial ovarian cancer. Br J Cancer 65, 621 623.
121. Emons G, Ortmann O, Teichert HM, Fassl H, Lohrs U, Kullander S, Kauppila A, Ayalon D, Schally A Oberheuser F (1996) Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 78, 1452 1460.
122. Medl M, Peters-Engel C, Fuchs G Leodolter S (1993) Triptorelin (D-Trp-6-LHRH) in combination with carboplatin-containing polychemotherapy for advanced ovarian cancer: a pilot study. Anticancer Res 13, 2373 2376.
123. Falkson CI, Falkson HC Falkson G (1996) Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin. Oncology 53, 313 317.
124. Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J Verschraegen C (2003) GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 10, 291 299.
125. Felberbaum RE, Ludwig M Diedrich K (2000) Clinical application of GnRH-antagonists. Mol Cell Endocrinol 166, 9 14.
126. Verschraegen CF, Westphalen S, Hu W, Loyer E, Kudelka A, Volker P, Kavanagh J, Steger M, Schulz KD Emons G (2003) Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol 90, 552 559.
127. Grundker C, Gunthert AR, Hellriegel M Emons G (2004) Gonadotropin- releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. Eur J Endocrinol 151, 619 628.